ORMP - Oramed Pharmaceuticals Inc.
| Previous Close | 5.18 |
| Open | 5.26 |
| Bid | 5.07 x 1800 |
| Ask | 5.10 x 1100 |
| Day's Range | 5.01 - 5.29 |
| 52 Week Range | 2.32 - 6.05 |
| Volume | 88,150 |
| Avg. Volume | 232,327 |
| Market Cap | 90.098M |
| Beta (5Y Monthly) | 1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.72 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.50 |
- Yahoo Finance Video
Oramed working on first insulin pill for diabetes
Oramed Pharmaceuticals is waiting on approval from the FDA after its new insulin pill to treat type two diabetes had successful results in its phase two trial. Oramed Pharmaceuticals CEO Nadav Kidron joins Yahoo Finance’s Brian Sozzi and Alexis Christoforous to discuss on The First Trade.
- PR Newswire
Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board
NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Board.
- PR Newswire
Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Jay Skyler, MD to its Scientific Advisory Board.
- PR Newswire
Oramed Pharmaceuticals Issues Letter to Shareholders
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following letter to shareholders from Chief Executive Officer Nadav Kidron. For a video message from Mr. Kidron click here.
- Simply Wall St.
Does Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Pay Compare Well With Peers?
Nadav Kidron became the CEO of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in 2006. First, this article will compare CEO...
- Zacks Small Cap Research
ORMP: Multiple Data Readouts on the Horizon…
By Anita Dushyanth, PhD NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Financial Update On November 27, 2019, Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) filed form 10-K with financial results for the fiscal year 2019 ending August 31, 2019. The company reported revenues of $2.7 million for the fiscal year 2019 compared to $2.4 million for 2018. The revenues are related to the license agreement
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Oramed Pharmaceuticals Inc. (ORMP)
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]
- PR Newswire
Oramed Appoints Dr. Arie Mayer to Board of Directors
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Arie Mayer, Ph.D. to its Board of Directors.
- Simply Wall St.
Introducing Oramed Pharmaceuticals (NASDAQ:ORMP), The Stock That Dropped 41% In The Last Three Years
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shareholders will doubtless be very grateful to see the share price up 32...
- PR Newswire
Oramed to Present a Scientific Poster at International Diabetes Federation Congress
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it will present a scientific poster at the 2019 International Diabetes Federation (IDF) Congress in Busan, South Korea to be held December 2-6. Oramed's Chief Scientific Officer, Dr. Miriam Kidron, will present the poster.
- PR Newswire
Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology
NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Japanese patent for the technology "Protease Inhibitor – Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same" has been granted by the Japanese Patent Office. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center.
- PR Newswire
Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event
NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, conducted an investor event and conference call yesterday, November 18, 2019, where a panel of investigators and Key Opinion Leaders presented detailed findings from the Company's successful Phase IIb study of ORMD-0801 in the treatment of type 2 diabetes. Panelists presenting the data included: Dr. Joel Neutel, Principal Investigator of the study and Director of Research at Orange County Research Center; Kenneth Homer, the trial's biostatistician; Dr. Ramachandra Naik, Professor of Medicine/Endocrinology at SUNY Upstate Medical University; and Dr. Alexander Fleming, CEO of Kinexum, and former Head of Clinical Review of Endocrine and Metabolic Drugs at the U.S. Food and Drug Administration (FDA).
- PR Newswire
Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th
NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center.
- PR Newswire
Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes
NEW YORK, November 12, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes.
- Simply Wall St.
How Does Investing In Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Impact The Volatility Of Your Portfolio?
Anyone researching Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) might want to consider the historical volatility of the...
- Simply Wall St.
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- PR Newswire
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference
NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company's Chief Executive Officer, Nadav Kidron, will present and participate in one-on-one meetings at the 2019 Ladenburg Thalmann Healthcare Conference to be held on September 24, 2019 in New York, NY.
- PR Newswire
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801
The Phase IIb double-blind, randomized, 90-day dose-ranging trial will assess the primary efficacy endpoint of reduction in HbA1c, as well as safety endpoints. Topline data from the primary cohort of the Phase IIb trial are expected to be released in the fourth quarter of 2019. Oramed Chief Executive Officer Nadav Kidron said, "Our lead oral insulin program could be a major advancement for the diabetes community as we believe it should offer a healthier way to treat diabetes.
- PR Newswire
Oramed to Present at Three Upcoming Conferences
NEW YORK , Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...
- Simply Wall St.
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Insiders Increased Their Holdings
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- Simply Wall St.
What Kind Of Investor Owns Most Of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)?
Every investor in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) should be aware of the most powerful shareholder groups...
- PR Newswire
Oramed to Present at World Diabetes Congress
NEW YORK , July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...
- PR Newswire
Oramed Announces Xiaoming Gao Joins Board of Directors
Mr. Gao is the Chairman of Hefei Tianhui Incubator of Technologies Co. Ltd. ("HTIT"), which signed a strategic licensing partnership with Oramed in November 2015 to bring oral insulin to China. In 2005, Mr. Gao invested and established Hefei Life Science and Technology Park Investment and Development Co., LTD., and led the existing team to successfully complete the registration of imported Insulin-SciLin in China from 2005 to 2009, and obtained the Imported Drug License.
- Zacks Small Cap Research
ORMP: Phase 2b Trial of ORMD-0801 Fully Enrolled; Data Expected 4Q19…
Oramed Pharmaceuticals Inc. (ORMP) is a biotechnology company with a proprietary oral protein delivery platform technology. The lead development candidate is ORMD-0801, an oral insulin, that is currently being tested in both type 1 (T1D) and type 2 diabetics (T2D). The company is also developing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1), and an oral leptin for the treatment of obesity in patients with T1D.
- PR Newswire
Oramed Provides Clinical Update with Meaningful Data Expected by Year-End
Completed recruitment and randomization of all patients in the primary cohort of Phase IIb HbA1c trial for oral insulin capsule ORMD-0801, potentially the first commercial oral insulin capsule for the ...
